The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing
Open accessAbstract
Endosomal escape remains a fundamental barrier hindering the advancement of nucleic acid therapeutics. Taking inspiration from natural phospholipids that comprise biological membranes, we report the combinatorial synthesis of multi-tailed ionizable phospholipids (iPhos) capable of delivering messenger RNA or mRNA/single-guide RNA for gene editing in vivo. Optimized iPhos lipids are composed of one pH-switchable zwitterion and three hydrophobic tails, which adopt a cone shape in endosomal acidic environments to facilitate membrane hexagonal transformation and subsequent cargo release from endosomes. Structure-activity relationships reveal that iPhos chemical structure can control in vivo efficacy and organ selectivity. iPhos lipids synergistically function with various helper lipids to formulate multi-component lipid nanoparticles (called iPLNPs) for selective organ targeting. Zwitterionic, ionizable cationic and permanently cationic helper lipids enable tissue-selective mRNA delivery and CRISPR-Cas9 gene editing in spleen, liver and lungs (respectively) following intravenous administration. This rational design of functional phospholipids demonstrates substantial value for gene editing research and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Organ selectivity can also be achieved by adjusting the proportions of lipid components, for example, to design spleen-targeted mRNA vaccines26,27 or lung-targeted genome editing delivery systems114,134.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
In the citing paper
“For example, alteration of the alkyl length of a lipid results in selective accumulation of lipid nanoparticle–mRNA formulations in the liver or spleen114.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Membrane lipids: where they are and how they behave
van Meer, G., Voelker, D. R., & Feigenson, G. W. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2330 · Cited by 7,157
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Self-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
Dilliard, S. A., Cheng, Q., & Siegwart, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109256118 · Cited by 1,018
Self-citationChemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 917
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 744
Self-citationLipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 649
An ionizable lipid toolbox for RNA delivery
Han, X., Zhang, H., Butowska, K., Swingle, K. L., Alameh, M.-G., Weissman, D., & Mitchell, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-27493-0 · Cited by 628
Wang, X., Liu, S., Sun, Y., Yu, X., Lee, S. M., Cheng, Q., Wei, T., Gong, J., Robinson, J. J., Zhang, D., et al. (2022) · Nature Protocols · doi:10.1038/s41596-022-00755-x · Cited by 581
Self-citationAdvances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 533
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 506
Self-citationEmerging non-viral vectors for gene delivery
Wang, C., Pan, C., Yong, H., Wang, F., Bo, T., Zhao, Y., Ma, B., He, W., & Li, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02044-5 · Cited by 325
“Taking inspiration from the natural phospholipids of biological membranes and the structure of cationic lipids, Liu et al. prepared 572 phospholipid molecules that feature pH-switchable, zwitterion, and three hydrophobic tails for mRNA delivery and CRISPR-Cas9 gene editing [7].”
BackgroundA novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems
Packer, M., Gyawali, D., Yerabolu, R., Schariter, J., & White, P. (2021) · Nature Communications · doi:10.1038/s41467-021-26926-0 · Cited by 279
Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation
Kim, J., Jozić, A., Lin, Y., Eygeris, Y., Bloom, E., Tan, X., Acosta, C., MacDonald, K. D., Welsher, K., & Sahay, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c05647 · Cited by 292
Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
Su, K., Shi, L., Sheng, T., Yan, X., Lin, L., Meng, C., Wu, S., Chen, Y., Zhang, Y., Wang, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50093-7 · Cited by 292
“To validate the cell type-speci fi c mRNA translation, weutilized a Cre-LoxP mouse model containing Lox-Stop-Lox cassette to prevent tdTomato expression 7,29,49 .”
Self-citationLipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
Zheng, L., Bandara, S. R., Tan, Z., & Leal, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301067120 · Cited by 283
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery
Sun, D., & Lu, Z. (2023) · Pharmaceutical Research · doi:10.1007/s11095-022-03460-2 · Cited by 253
AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery
Xu, Y., Ma, S., Cui, H., Chen, J., Xu, S., Gong, F., Golubovic, A., Zhou, M., Wang, K. C., Varley, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50619-z · Cited by 285
“Atthehigh-throughputscreeningstage, the synthesized ionizable lipids were not puri fi ed before LNP formulation and the concentrations of crude lipids were estimated based on average reaction yields obtained from preliminary studies 15,16,45,56 .”
Emerging mRNA technologies: delivery strategies and biomedical applications
Xiao, Y., Tang, Z., Huang, X., Chen, W., Zhou, J., Liu, H., Liu, C., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00617g · Cited by 255
Zhang, D., Wang, G., Yu, X., Wei, T., Farbiak, L., Johnson, L. T., Taylor, A. M., Xu, J., Hong, Y., Zhu, H., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01122-3 · Cited by 243
Self-citationLi, B., Raji, I. O., Gordon, A. G. R., Sun, L., Raimondo, T. M., Oladimeji, F. A., Jiang, A. Y., Varley, A., Langer, R. S., & Anderson, D. G. (2024) · Nature Materials · doi:10.1038/s41563-024-01867-3 · Cited by 236
“Moreover, to assess the lipid 119-23’s transfection efficacy in other key organs, we employed a five-component ‘selective organ targeting’ (SORT) formulation 29,30 to direct LNPs specifically to the lungs.”
Álvarez‐Benedicto, E., Farbiak, L., Ramírez, M. M., Wang, X., Johnson, L. T., Mian, O. T., Guerrero, E. D., & Siegwart, D. J. (2021) · Biomaterials Science · doi:10.1039/d1bm01454d · Cited by 235
Self-citationMelamed, J. R., Yerneni, S. S., Arral, M. L., LoPresti, S. T., Chaudhary, N., Sehrawat, A., Muramatsu, H., Alameh, M., Pardi, N., Weissman, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1444 · Cited by 218
In vivo somatic cell base editing and prime editing
Newby, G. A., & Liu, D. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.002 · Cited by 195
Combinatorial development of nebulized mRNA delivery formulations for the lungs
Jiang, A. Y., Witten, J. J., Raji, I. O., Eweje, F., MacIsaac, C., Meng, S., Oladimeji, F. A., Hu, Y., Manan, R. S., Langer, R., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01548-3 · Cited by 215
“To test whether we could screen the lipids without individual purification as has been done with other libraries 6,66,67 , we prepared 22 lipids, both purified and crude, formulated into LNPs using the T1-5 formulation, and tested their FFL mRNA delivery in A549 cells.”
Wei, T., Sun, Y., Cheng, Q., Chatterjee, S., Traylor, Z., Johnson, L. T., Coquelin, M. L., Wang, J., Torres, M. J., Lian, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42948-2 · Cited by 207
Self-citationNucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 225
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 189
Liu, S., Wang, X., Yu, X., Cheng, Q., Johnson, L. T., Chatterjee, S., Zhang, D., Lee, S. M., Sun, Y., Lin, T., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09822 · Cited by 175
Self-citationMembrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment
Guo, S., Li, K., Hu, B., Li, C., Zhang, M., Hussain, A., Wang, X., Cheng, Q., Yang, F., Ge, K., et al. (2021) · Exploration · doi:10.1002/exp.20210008 · Cited by 176
Self-citationRecent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
“Ionizable phospholipids can also be combined with the charged helper lipids to achieve gene editing in the lung, liver and spleen 215 .”
BackgroundWang, Y., Kumari, M., Chen, G., Hong, M.-H., Yuan, J. P., Tsai, J.-L., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 198
Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Designer phospholipid capping ligands for soft metal halide nanocrystals
Morad, V., Stelmakh, A., Svyrydenko, M., Feld, L. G., Boehme, S. C., Aebli, M., Affolter, J., Kaul, C. J., Schrenker, N. J., Bals, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06932-6 · Cited by 172
“…has already been extensively studied with a multitude of optimized reactions 30 , owing to the prevalence of PC lipids in biological membranes 38 and their broad use for engineering liposomes for medical applications (for example, drug or gene delivery) 24,39,40 or as drugs on their own 41,42 .”
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177
Self-citationArtificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy
Witten, J. J., Raji, I. O., Manan, R. S., Beyer, E., Bartlett, S., Tang, Y., Ebadi, M., Lei, J., Nguyen, D., Oladimeji, F. A., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02490-y · Cited by 197
Nanotechnology Strategies for Plant Genetic Engineering
Yan, Y., Zhu, X., Yu, Y., Li, C., Zhang, Z., & Wang, F. (2021) · Advanced Materials · doi:10.1002/adma.202106945 · Cited by 164
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 160
“LNP-mediated transfection of the spleen macrophages was achieved using multi-tailed ionizable phospho-lipids when longer carbon chains were introduced, suggesting a structure–activity relationship of the ionizable phospholipids for organ-selective transfection 90 .”
Mrksich, K., Padilla, M. S., & Mitchell, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115446 · Cited by 162
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 148
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 147
Lian, X., Chatterjee, S., Sun, Y., Dilliard, S. A., Moore, S., Xiao, Y., Bian, X., Yamada, K., Sung, Y., Levine, R. M., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01680-8 · Cited by 140
“…development of selective organ targeting (SORT) LNPs, in which the addition of a defined amount of ionizable lipids, positively charged lipids or negatively charged lipids to the base-4-lipid LNP formulation, leads to exclusive mRNA delivery to the liver, lungs and spleen, respectively 37,41,44 .”
Self-citationDesign of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 143
Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery
Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202303266 · Cited by 142
Pattipeiluhu, R., Zeng, Y., Hendrix, M. M. R. M., Voets, I. K., Kros, A., & Sharp, T. H. (2024) · Nature Communications · doi:10.1038/s41467-024-45666-5 · Cited by 132
“These fi ndingsarecomplementarytotherationale for which membrane-disrupting ILs or LNP formulations were designed, in which ILs form non-lamellar structures with the anionic lipids of the acceptor membrane 18,19 .”
Huang, X., Chuang, L. I. U., Kong, N., Xiao, Y., Yurdagul, A., Tabas, I. A., & Tao, W. (2022) · Nature Protocols · doi:10.1038/s41596-021-00665-4 · Cited by 126
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 131
Xue, L., Zhao, G., Gong, N., Han, X., Shepherd, S. J., Xiong, X., Xiao, Z., Palanki, R., Xu, J., Swingle, K. L., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01747-6 · Cited by 141
“12–20) and the resulting SiLNPs were characterized 14,24,25 (Supplementary Fig.”
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
Novel Drug Delivery Systems: An Important Direction for Drug Innovation Research and Development
Chen, Q., Yang, Z., Liu, H., Man, J., Oladejo, A. O., Ibrahim, S., Wang, S., & Hao, B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050674 · Cited by 134
“Shuai et al. [23] have pioneered a novel LNP delivery system (iPLNPs), which incorporates novel phospholipids (iPhos) with enhanced endocytic escape capabilities.”
BackgroundMicrofluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
Prakash, G., Shokr, A., Willemen, N. G. A., Bashir, S. M., Shin, S. R., & Hassan, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114197 · Cited by 122
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 117
Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections
Abramson, A., Kirtane, A. R., Shi, Y., Zhong, G., Collins, J. E., Tamang, S. M., Ishida, K., Hayward, A. M., Wainer, J., Rajesh, N. U., et al. (2022) · Matter · doi:10.1016/j.matt.2021.12.022 · Cited by 110
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
Delivering on the promise of protein degraders
O’Brien, M. N., Luthra, S. A., Brown, M. F., & Bartlett, D. W. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00652-2 · Cited by 109
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 124
“LNPs formulated with 9A1P9 also demonstrated superior function according to mRNA expression and efficiency of CRISPR-Cas9 gene editing in liver and lung tissues [150].”
BackgroundRecent advances in nanoparticulate RNA delivery systems
Witten, J. J., Hu, Y., Langer, R., & Anderson, D. G. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307798120 · Cited by 113
“…reported the combinatorial synthe - sis of an ionizable phospholipid (iPhos) library via a ring - opening reaction in which the top iPhos showed potent in vivo mRNA delivery (70), as well as zwitterionic amino lipids (ZALs) that eliminate the requirement for a helper phospho - lipid (71).”
BackgroundChen, Z., Tian, Y., Yang, J., Wu, F., Liu, S., Cao, W., Xu, W., Hu, T., Siegwart, D. J., & Xiong, H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09143 · Cited by 108
Self-citationCarrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 105
Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery
Xu, X., & Xia, T. (2023) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.2c00062 · Cited by 106
Lipid in Chips: A Brief Review of Liposomes Formation by Microfluidics
Guo, Z., & Sun, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s331639 · Cited by 110
Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma
Yin, H., Sun, L., Pu, Y., Yu, J., Feng, W., Dong, C., Zhou, B., Du, D., Zhang, Y., Chen, Y., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c01143 · Cited by 102
Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective
Ferhan, A. R., Park, S.-H., Park, H., Tae, H., Jackman, J. A., & Cho, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203669 · Cited by 103
Li, Y., Ye, Z., Yang, H., & Xu, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.013 · Cited by 103
Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery
Cárdenas, M., Campbell, R. A., Arteta, M. Y., Lawrence, M. J., & Sebastiani, F. (2023) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2023.101705 · Cited by 108
“Liu et al. [55] demonstrated that improved mRNA delivery could be obtained by tuning the chemical structure of the ionizable lipid.”
BackgroundHaghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 125
Omo‐Lamai, S., Wang, Y., Patel, M. N., Milosavljevic, A., Zuschlag, D. W., Poddar, S., Wu, J., Wang, L., Dong, F., Espy, C. L., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01974-5 · Cited by 170
“Once protonated in the acidic endosome, ionizable lipids form ion pairs with the anionic lipids in the endosomal membrane, leading to the formation of an inverse hexagonal phase that disrupts the endosomal membrane and releases the RNA cargo into the cytosol 31–33 .”
Pan, L., Zhang, L., Deng, W., Lou, J., Gao, X., Lou, X., Liu, Y., Yao, X., Sheng, Y., Yan, Y., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.041 · Cited by 100
‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
Fu, L., Zhang, Y., Farokhzad, R. A., Mendes, B. B., Conde, J., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00998f · Cited by 100
A Combinatorial Library of Lipid Nanoparticles for Cell Type‐Specific mRNA Delivery
Naidu, G. S., Yong, S., Ramishetti, S., Rampado, R., Sharma, P., Ezra, A., Goldsmith, M., Hazan‐Halevy, I., Chatterjee, S., Aitha, A., et al. (2023) · Advanced Science · doi:10.1002/advs.202301929 · Cited by 104
Huang, P., Jiang, L., Pan, H., Ding, L., Zhou, B., Zhao, M., Zou, J., Li, B., Qi, M., Deng, H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207471 · Cited by 96
Dong, W. X., Li, Z., Hou, T., Shen, Y., Guo, Z., Su, Y., Chen, Z., Pan, H., Jiang, W., & Wang, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c00451 · Cited by 96
Han, X., Alameh, M., Gong, N., Xue, L., Ghattas, M., Bojja, G., Xu, J., Zhao, G., Warzecha, C. C., Padilla, M. S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01557-2 · Cited by 100
“…there has been a growing interest in genome editing through the co-delivery of Cas9 mRNA and sgRNA, as exemplified by Intellia’s LNP-mediated liver transthyretin ( TTR ) knockout 40 , yet few studies have successfully used this combination to knock out an endogenous gene in the lung 37,41 .”
BackgroundEngineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy
Yu, J., Zhou, B., Zhang, S., Yin, H., Sun, L., Pu, Y., Zhou, B., Sun, Y., Li, X., Fang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35580-z · Cited by 98
Biomimetic noncationic lipid nanoparticles for mRNA delivery
Wang, C., Zhao, C., Wang, W., Liu, X., & Deng, H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2311276120 · Cited by 91
Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo
Zhang, T., Yin, H., Li, Y., Yang, H., Ge, K., Zhang, J., Yuan, Q., Dai, X., Naeem, A., Weng, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109804 · Cited by 99
“47 Similarly,bothzwitterionicaminolipidsandcationicquaternarysulfonamideaminolipidshavepermanentcationicquaternaryammo-nium functional groups and can also be used to design lung-targeted LNPs. 25 The more detailed LNPs compositions for extrahepatic delivery are summarized by Dilliard S.A. and…”
BackgroundInfluentialFei, Y., Yu, X., Liu, P., Ren, H., Wei, T., & Cheng, Q. (2024) · Advanced Materials · doi:10.1002/adma.202409812 · Cited by 99
Self-citationmRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 98
“Using the SORT strategy, Siegwart et al. [106, 116, 155] added 50% permanently cationic lipids containing quaternary amino groups, such as DOTAP, Dimethyldido-decylammonium bromide (DDAB), and EPC, into the traditional mRNA-LNP formulation that was initially intended for liver targeting.”
BackgroundMethodFluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency
Zhang, H., Meng, C., Yi, X., Han, J., Wang, J., Liu, F., Ling, Q., Li, H., & Gu, Z. (2024) · ACS Nano · doi:10.1021/acsnano.3c04507 · Cited by 91
“Targeting Design” of Nanoparticles in Tumor Therapy
Yang, T., Zhai, J., Hu, D., Yang, R., Wang, G., Li, Y., & Liang, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091919 · Cited by 87
Johnson, L. T., Zhang, D., Zhou, K., Lee, S. M., Liu, S., Dilliard, S. A., Farbiak, L., Chatterjee, S., Lin, Y.-H., & Siegwart, D. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00442 · Cited by 85
Self-citationROS-Responsive Nanoparticle Delivery of mRNA and Photosensitizer for Combinatorial Cancer Therapy
Zhou, H., Liao, Y., Han, X., Chen, D. S., Hong, X., Zhou, K., Jiang, X., Xiao, Y., & Shi, J. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c03784 · Cited by 83
Catenacci, L., Rossi, R., Sechi, F., Buonocore, D., Sorrenti, M., Perteghella, S., Peviani, M., & Bonferoni, M. C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121521 · Cited by 86
“To enrich the diversity of phospholipids and, more importantly, to optimize the physical and biological functions of these carriers in SLNs, Liu et al. developed a new type of multi-tailed ionizable phospholipids (iPhos) [111].”
Cui, L., Hunter, M. R., Sonzini, S., Pereira, S. G. T., Romanelli, S. M., Liu, K., Li, W., Liang, L., Yang, B., Mahmoudi, N., et al. (2021) · Small · doi:10.1002/smll.202105832 · Cited by 78
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy
Sun, Y., Sha, Y., Cui, G., Meng, F., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114624 · Cited by 78
Tuning Lipid Nanoparticles for RNA Delivery to Extrahepatic Organs
Song, D., Zhao, Y., Wang, Z., & Xu, Q. (2024) · Advanced Materials · doi:10.1002/adma.202401445 · Cited by 87
Xiao, Y., Lian, X., Sun, Y., Sung, Y., Vaidya, A., Chen, Z., Gupta, A., Chatterjee, S., Zheng, L., Guerrero, E. D., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02116-3 · Cited by 87
“16–18).”
Self-citationAdvanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 77
Song, Z., Tao, Y., Liu, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444437 · Cited by 81
“The CRISPR/Cas9 system may be neutralized or degraded in the complex in vivo microenvironment as a result of the immune response or other physical, chemical, or biological constraints (90, 91).”
BackgroundLipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 75
“These lipids can function together with additional variously charged helper lipids to allow organ-specific delivery, an approach similar to the SORT system [78].”
mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy
Sasaki, K., Sato, Y., Okuda, K., Iwakawa, K., & Harashima, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081572 · Cited by 80
One‐Component Cationic Lipids for Systemic mRNA Delivery to Splenic T Cells
Zhang, X., Su, K., Wu, S., Lin, L., He, S., Yan, X., Shi, L., & Liu, S. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202405444 · Cited by 76
Self-citationDong, S., Feng, Z., Ma, R., Zhang, T., Jiang, J., Li, Y., Zhang, Y., Li, S., Liu, X., Liu, X., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04486 · Cited by 76
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 76
“The high-throughput method has also been applied by Siegwart’s research group for ionizable phospholipid screening to deliver mRNA and single-guide RNA (sgRNA) to facilitate gene-editing therapy in lung, spleen, and liver, respectively [45].”
Method
Metadata
- Authors
- Liu, S., Cheng, Q., Wei, T., Yu, X., Johnson, L. T., Farbiak, L., & Siegwart, D. J.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Siegwart, Daniel J.
- Venue
- Nature Materials
- Published
- 2021-02-04
- Volume
- 20
- Issue
- 5
- Pages
- 701-710
- ISSN
- 1476-1122 (ISSN-L)
- 1476-4660
- PMC
- PMC8188687
- OpenAlex
- W3127944141
- Cited by
- 653
- References
- 54
- Citations by year
- 2026: 107 · 2025: 154 · 2024: 139 · 2023: 122 · 2022: 90 · 2021: 40
- FWCI
- 30.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Materials (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP160157)
- U.S. Department of Health & Human Services | National Institutes of Health (R01 EB025192-01A1)
- American Cancer Society (RSG-17-012-01)
- Welch Foundation (I-1855)
- Cystic Fibrosis Foundation (SIEGWA18XX0)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P30CA142543)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- endosomal escape, mRNA delivery, CRISPR/Cas9 genome editing, lipid nanoparticles, zwitterionic lipids, membrane perturbation, structure-activity relationship, helper lipids, nucleic acid therapeutics
- MeSH terms
- Gene Editing, Animals, Cell Line, Cell Membrane, Female, Organ Specificity, Phospholipids, RNA, Messenger, Drug Delivery Systems, Mice, Administration, Intravenous, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
